The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 09 2023
Historique:
received: 14 03 2023
accepted: 15 09 2023
medline: 22 9 2023
pubmed: 21 9 2023
entrez: 21 9 2023
Statut: epublish

Résumé

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The pathological hallmark of PD is the appearance of intraneuronal cytoplasmic α-synuclein (α-Syn) aggregation, called Lewy bodies. α-Syn aggregation is deeply involved in the pathogenesis of PD. Oxidative stress is also associated with the progression of PD. In the present study, to investigate whether a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PH) inhibitor, FG-4592 (also called roxadustat), has neuroprotective effects against α-Syn-induced neurotoxicity, we employed a novel α-Syn stably expressing cell line (named α-Syn-N2a cells) utilizing a piggyBac transposon system. In α-Syn-N2a cells, oxidative stress and cell death were induced by α-Syn, and FG-4592 showed significant protection against this neurotoxicity. However, FG-4592 did not affect α-Syn protein levels. FG-4592 triggered heme oxygenase-1 (HO-1) expression downstream of HIF-1α in a concentration-dependent manner. In addition, FG-4592 decreased the production of reactive oxygen species possibly via the activation of HO-1 and subsequently suppressed α-Syn-induced neurotoxicity. Moreover, FG-4592 regulated mitochondrial biogenesis and respiration via the induction of the peroxisome proliferator-activated receptor-γ coactivator-1α. As FG-4592 has various neuroprotective effects against α-Syn and is involved in drug repositioning, it may have novel therapeutic potential for PD.

Identifiants

pubmed: 37731009
doi: 10.1038/s41598-023-42903-7
pii: 10.1038/s41598-023-42903-7
pmc: PMC10511692
doi:

Substances chimiques

Prolyl Hydroxylases EC 1.14.11.-
alpha-Synuclein 0
Neuroprotective Agents 0
Prolyl-Hydroxylase Inhibitors 0
Procollagen-Proline Dioxygenase EC 1.14.11.2
Glycine TE7660XO1C

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15629

Informations de copyright

© 2023. Springer Nature Limited.

Références

Sci Rep. 2020 Dec 17;10(1):22157
pubmed: 33335227
Trends Mol Med. 2003 Aug;9(8):360-5
pubmed: 12928038
Cell Stem Cell. 2022 Feb 3;29(2):189-208
pubmed: 35120619
Ann Neurol. 2022 Nov;92(5):715-724
pubmed: 35913124
Cell Prolif. 2020 Nov;53(11):e12909
pubmed: 32975326
Neurobiol Dis. 2019 Dec;132:104582
pubmed: 31445162
Prog Neurobiol. 2021 Jul;202:102070
pubmed: 33951536
Autophagy. 2019 Jan;15(1):113-130
pubmed: 30160596
Front Aging Neurosci. 2018 Apr 27;10:121
pubmed: 29755339
N Engl J Med. 2022 Aug 4;387(5):408-420
pubmed: 35921450
J Biol Chem. 1999 Nov 12;274(46):32631-7
pubmed: 10551817
CNS Neurosci Ther. 2022 Oct;28(10):1519-1531
pubmed: 35695696
Neurobiol Dis. 2023 Feb;177:105969
pubmed: 36535551
Biology (Basel). 2021 Jul 29;10(8):
pubmed: 34439955
J Neurosci. 2014 Jun 4;34(23):8043-50
pubmed: 24899725
Neurobiol Dis. 2019 Apr;124:276-288
pubmed: 30381260
J Pharmacol Sci. 2006 Oct;102(2):243-7
pubmed: 17038803
Mol Neurodegener. 2021 Jun 21;16(1):35
pubmed: 34148545
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808
pubmed: 32576618
Neurobiol Dis. 2020 Apr;137:104782
pubmed: 31991247
J Biol Chem. 2009 Oct 16;284(42):29065-76
pubmed: 19679656
Cell Rep. 2021 May 11;35(6):109099
pubmed: 33979611
N Engl J Med. 2022 Aug 4;387(5):421-432
pubmed: 35921451
Stem Cells Dev. 2016 Jul 15;25(14):1084-94
pubmed: 27224420
Curr Opin Neurobiol. 2023 Feb;78:102664
pubmed: 36535149
J Am Chem Soc. 2007 Aug 29;129(34):10324-5
pubmed: 17672465
Cell. 2006 Oct 20;127(2):397-408
pubmed: 17055439
Oxid Med Cell Longev. 2020 Jan 20;2020:6286984
pubmed: 32051732
Sci Rep. 2017 Jul 18;7(1):5768
pubmed: 28720798
Sci Rep. 2020 Jan 31;10(1):1597
pubmed: 32005890
Cell Death Dis. 2019 Nov 14;10(11):865
pubmed: 31727879
Int J Mol Sci. 2021 Oct 25;22(21):
pubmed: 34768913
Acta Neuropathol. 2011 Jul;122(1):75-86
pubmed: 21541762
Drug Discov Today. 2020 Jul;25(7):1262-1269
pubmed: 32380083
Nature. 2020 Feb;578(7795):419-424
pubmed: 31996848
J Neuroinflammation. 2021 Jan 18;18(1):23
pubmed: 33461598
J Biol Chem. 2007 Jun 1;282(22):16413-22
pubmed: 17400550
Nat Neurosci. 2022 Sep;25(9):1134-1148
pubmed: 36042314

Auteurs

Ayaka Fujimaki (A)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.

Kazuki Ohuchi (K)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.

Shinnosuke Takizawa (S)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.

Takanori Murakami (T)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.

Hisaka Kurita (H)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.

Isao Hozumi (I)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.

Xiaopeng Wen (X)

Laboratory of Pharmacology and Neurobiology, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, 525-8577, Japan.

Yoshihisa Kitamura (Y)

Laboratory of Pharmacology and Neurobiology, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, 525-8577, Japan.

Zhiliang Wu (Z)

Department of Parasitology and Infectious Diseases, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Yoichi Maekawa (Y)

Department of Parasitology and Infectious Diseases, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
Division of Preemptive Food Research, Preemptive Food Research Center (PFRC), Gifu University Institute for Advanced Science (GUIAS), Gifu, 501-1194, Japan.
Division of Animal Medical Science, Center for One Medicine Innovative Translational Research (COMIT), Gifu University Institute for Advanced Science (GUIAS), Gifu, 501-1194, Japan.

Masatoshi Inden (M)

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, 501-1196, Japan. inden@gifu-pu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH